Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy!

Comment

Rita Jacobs et al. Crit Care. 2015.

. 2015 Feb 6;19(1):50.

doi: 10.1186/s13054-015-0766-3.

No abstract available

Comment on

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.
Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, Vervloet MG, Beishuizen A, Girbes AR, Ter Wee PM, Groeneveld AB; CASH study group. Schilder L, et al. Crit Care. 2014 Aug 16;18(4):472. doi: 10.1186/s13054-014-0472-6. Crit Care. 2014. PMID: 25128022 Free PMC article. Clinical Trial.

1. Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care. 2014;18:472. doi: 10.1186/s13054-014-0472-6. - DOI - PMC - PubMed
1. Oudemans-van Straaten HM. Citrate for continuous renal replacement therapy: safer, better and cheaper. Crit Care. 2014;18:661. doi: 10.1186/s13054-014-0661-3. - DOI - PMC - PubMed
1. Jacobs R, Honoré PM, De Regt J, De Waele E, Lochy S, Troubleyn J, et al. Type of citrate solution and filter lifespan during continuous renal replacement therapy [abstract] Intensive Care Med. 2013;39:S442–3.
1. Jacobs R, Honore PM, De Regt J, de Mars M, Spapen HD. Citrate during CRRT. In: Vuylsteke A, editor. Renal replacement therapy – core critical care. Cambridge, UK: Cambridge University Press; 2015.
1. Egi M, Naka T, Bellomo R. The acid–base effect of changing citrate solution for regional anticoagulation during continuous veno-venous hemofiltration. Int J Artif Organs. 2008;31:228–36. - PubMed